| Literature DB >> 28739600 |
Joseph R Owen1, Noelle Noyes2, Amy E Young1, Daniel J Prince1, Patricia C Blanchard3, Terry W Lehenbauer4,5, Sharif S Aly4,5, Jessica H Davis4, Sean M O'Rourke1, Zaid Abdo2, Keith Belk6, Michael R Miller1, Paul Morley7, Alison L Van Eenennaam8,4.
Abstract
Extended laboratory culture and antimicrobial susceptibility testing timelines hinder rapid species identification and susceptibility profiling of bacterial pathogens associated with bovine respiratory disease, the most prevalent cause of cattle mortality in the United States. Whole-genome sequencing offers a culture-independent alternative to current bacterial identification methods, but requires a library of bacterial reference genomes for comparison. To contribute new bacterial genome assemblies and evaluate genetic diversity and variation in antimicrobial resistance genotypes, whole-genome sequencing was performed on bovine respiratory disease-associated bacterial isolates (Histophilus somni, Mycoplasma bovis, Mannheimia haemolytica, and Pasteurella multocida) from dairy and beef cattle. One hundred genomically distinct assemblies were added to the NCBI database, doubling the available genomic sequences for these four species. Computer-based methods identified 11 predicted antimicrobial resistance genes in three species, with none being detected in M. bovis While computer-based analysis can identify antibiotic resistance genes within whole-genome sequences (genotype), it may not predict the actual antimicrobial resistance observed in a living organism (phenotype). Antimicrobial susceptibility testing on 64 H. somni, M. haemolytica, and P. multocida isolates had an overall concordance rate between genotype and phenotypic resistance to the associated class of antimicrobials of 72.7% (P < 0.001), showing substantial discordance. Concordance rates varied greatly among different antimicrobial, antibiotic resistance gene, and bacterial species combinations. This suggests that antimicrobial susceptibility phenotypes are needed to complement genomically predicted antibiotic resistance gene genotypes to better understand how the presence of antibiotic resistance genes within a given bacterial species could potentially impact optimal bovine respiratory disease treatment and morbidity/mortality outcomes.Entities:
Keywords: Histophilus somni; Mannheimia haemolytica; Mycoplasma bovis; Pasteurella multocida
Mesh:
Substances:
Year: 2017 PMID: 28739600 PMCID: PMC5592931 DOI: 10.1534/g3.117.1137
Source DB: PubMed Journal: G3 (Bethesda) ISSN: 2160-1836 Impact factor: 3.154
Known reference sequences for the species sequenced in this study
| Strain | GenBank Accession | Publication |
|---|---|---|
| 2336 | GCA_000019405.1 | |
| 129PT | GCA_000011785.1 | |
| Hubei1 | GCA_000219375.1 | |
| HB0801 | GCA_000270525.1 | |
| CQ-W70 | GCA_000696015.1 | None |
| NM2012 | GCA_000183385.1 | |
| PG45 | GCA_001043135.1 | None |
| M42548 | GCA_000376645.1 | |
| 89010807N_lktA | GCA_000963675.1 | |
| D153 | GCA_000422145.1 | |
| D171 | GCA_000427275.1 | |
| D174 | GCA_000422095.1 | |
| 89010807N | GCA_000963635.1 | |
| USDA-ARS-SAM-185 | GCA_000349785.1 | |
| USDA-ARS-USMARC-183 | GCA_000349765.1 | |
| USDA-ARS-USMARC-184 | GCA_000819525.1 | None |
| USMARC_2286 | GCA_000439735.1 | |
| 36950 | GCA_000234745.1 | |
| 3480 | GCA_000259545.1 | None |
| ATCC_43137 | GCA_000754275.1 | |
| HB01 | GCA_001663095.1 | |
| HB03 | GCA_000512395.1 | None |
| HN06 | GCA_000255915.1 | |
| OH1907 | GCA_000973565.1 | None |
| OH4807 | GCA_000973525.1 | None |
| PMTB2.1 | GCA_001578435.1 | None |
| Pm-3 | GCA_001721885.1 | None |
| Pm70 | GCA_000006825.1 |
Growth conditions for each of the four species used during this study
| Species | Plate Media | Days for Growth | Broth Media | Days for Growth | Shaker | Environment |
|---|---|---|---|---|---|---|
| Columbia agar | 1–2 | BHI | 1–2 | N/A | Anaerobic | |
| PPLO | 5 | PPLO | 5 | N/A | 5% CO2 | |
| Sheep’s blood agar | 1–2 | BHI | 1–2 | 250 rpm | Facultative | |
| Sheep’s blood agar | 1–2 | BHI | 1–2 | 250 rpm | Facultative |
BHI, brain–heart infusion; PPLO, pleuropneumonia-like organism.
Primers and PCR amplification protocols used in this study
| Species | Primer | Sequence (5′-3′) | Tm (°) |
|---|---|---|---|
| Lob1F | 56.3 | ||
| Lob1R | 58.4 | ||
| MB528F | 58.4 | ||
| MB528R | 56.3 | ||
| LktF | 61 | ||
| LktR | 61.2 | ||
| KMT1SPG | 62.4 | ||
| KMT1T7 | 60.4 | ||
| Positive control | 16SF | 64.5 | |
| 16SR | 65.6 |
Mapping of identified resistance genes to antimicrobial drugs included on the broth microdilution phenotypic susceptibility panel
| Resistance Gene | Antibiotic (Abbreviation) | Antibiotic Class | CLSI Approved Breakpoint | Breakpoint (mg/ml) | ||
|---|---|---|---|---|---|---|
| Susceptible | Intermediate | Resistant | ||||
| Chlortetracycline (CHLOR) | Tetracycline | Yes | ≤2 | 4 | ≥8 | |
| Oxytetracycline (OXY) | Tetracycline | Yes | ≤2 | 4 | ≥8 | |
| Neomycin (NEO) | Aminoglycoside | No | ≤2 | 4 | ≥8 | |
| None tested | N/A | N/A | N/A | N/A | N/A | |
| None tested | N/A | N/A | N/A | N/A | N/A | |
| Ampicillin (AMP) | β-Lactam | Yes | ≤0.5 | 1 | ≥2 | |
| Ceftiofur (CEFT) | β-Lactam | Yes | ≤2 | 4 | ≥8 | |
| Penicillin (PEN) | β-Lactam | Yes | ≤0.25 | 0.5 | ≥1 | |
| Sulfadimethoxine (SUL) | Sulfonamide | Yes | ≤256 | — | ≥512 | |
| Trimethoprim-sulfamethoxazole (TMS) | Sulfonamide | Yes | <0.5 and 9.5 | 1–2 and 19–38 | 4 and 76 | |
| Clindamycin (CLIN) | MLS | Yes | ≤0.5 | 1 - 2 | ≥4 | |
| Tilmicosin (TIL) | MLS | Yes | ≤8 | 16 | ≥32 | |
| Tulathromycin (TUL) | MLS | Yes | ≤16 | 32 | ≥64 | |
| Tylosin tartrate (TYL) | MLS | No | ≤8 | 16 | ≥32 | |
| Florfenicol (FLOR) | Phenicol | Yes | ≤2 | 4 | ≥8 | |
| Florfenicol (FLOR) | Phenicol | Yes | ≤2 | 4 | ≥8 | |
| Trimethoprim-sulfamethoxazole (TMS) | TMS | Yes | <0.5 and 9.5 | 1–2 and 19–38 | 4 and 76 | |
| None identified | Danofloxacin (DAN) | Fluoroquinolone | Yes | ≤0.25 | — | — |
| None identified | Enrofloxacin (ENRO) | Fluoroquinolone | Yes | ≤0.25 | 0.5–1 | ≥2 |
| None identified | Gentamicin (GENT) | Aminoglycoside | Yes | ≤2 | 4 | ≥8 |
| None identified | Spectinomycin (SPEC) | Aminoglycoside | Yes | ≤32 | 64 | ≥128 |
| None identified | Tiamulin (TIA) | Pleuromutilin | Yes | ≤16 | — | ≥32 |
MLS, macrolide-lincosamide-streptogramin.
For Neomycin, we used NARMS 2011 breakpoints for aminoglyosides.
For Ampicillin, we used CLSI breakpoints for swine that were validated for the following bacteria: Actinobacillus pleuropneumoniae and P. multocida.
For Danofloxacin, we used CLSI breakpoints for cattle, but only validated for the following bacteria: M. haemolytica and P. multocida.
For Sulfadimethoxine and TMS, we used CLSI breakpoints for humans with systemic disease and validated in Enterobacteriaceae.
For Clindamycin, we used CLSI breakpoints for canines that were validated for the following bacteria: Staphylcoccus spp. and β-hemolytic Streptococci.
For Tilmicosin, we used CLSI breakpoints for cattle, but only validated for the following bacteria: M. haemolytica.
For Tylosin, we used the same breakpoints as in the following document: https://www.ars.usda.gov/SP2UserFiles/Place/60400520/NARMS/ABXEntero.pdf.
For Gentamicin, we used canine and equine breakpoints validated in Pseudomonas aeruginosa and Enterobacteriaceae and the equine breakpoint for Actinobacillus spp.
For Tiamulin, we used CLSI breakpoints for swine that were validated for the following bacteria: Actinobacillus pleuropneumoniae.
Average assembly statistics for each species sequenced in this study from de novo assembled contigs
| Species | Contig | Coverage | Total Length | N50 | Min. Contig | Max. Contig |
|---|---|---|---|---|---|---|
| 77 | 62.46 | 2,136,280 | 89,438 | 1094 | 294,083 | |
| 74 | 72.41 | 943,236 | 27,508 | 1061 | 59,658 | |
| 105 | 35.68 | 2,637,528 | 70,779 | 1068 | 282,147 | |
| 33 | 29.33 | 2,317,940 | 171,866 | 1099 | 469,530 |
Total length is the total of all contig lengths; N50 is 50% of the mass of distribution of the contig lengths; Min. contig and Max. contig are the length of the shortest and longest contigs in each assembly.
Figure 1Genetic distance trees from mapped assemblies of the four bacterial species, Histophilus somni aligned to reference sequence 2336, Mycoplasma bovis aligned to Hubei1, Mannheimia haemolytica aligned to reference sequence M42548, and Pasteurella multocida aligned to reference sequence 36950. Red circle, beef cattle; blue box, reference sequence; green box, M. haemolytica genotype 1 (Clawson ). Scale bar represents number of substitutions per site.
Figure 2Prevalence of resistance genes among isolates of Histophilus somni (N = 16), Mannheimia haemolytica (N = 29), and Pasteurella multocida (N = 35), as well as available reference sequences. +, present; −, absent.
Concordance of phenotypic and susceptibility results for all three organisms (64 isolates)
| Pheno: S | Pheno: R | |||||||
|---|---|---|---|---|---|---|---|---|
| Class | Antibiotic | Geno:R | Geno:S | Geno:R | Geno:S | Discordant (%) | Concordant (%) | |
| β-Lactam | Ampicillin | 4 | 42 | 15 | 3 | 11 | 89 | 0.73 |
| β-Lactam | Ceftiofur | 19 | 44 | 0 | 1 | 31 | 69 | <0.001 |
| β-Lactam | Penicillin | 4 | 41 | 15 | 4 | 13 | 88 | 0.99 |
| Tetracycline | Chlortetracycline | 53 | 1 | 10 | 0 | 83 | 17 | <0.001 |
| Tetracycline | Oxytetracycline | 1 | 1 | 62 | 0 | 2 | 98 | 0.50 |
| Fluoroquinolone | Danofloxacin | 0 | 44 | 0 | 20 | 31 | 69 | <0.001 |
| Fluoroquinolone | Enrofloxacin | 0 | 64 | 0 | 0 | 0 | 100 | 0.32 |
| Phenicol | Florfenicol | 24 | 26 | 14 | 0 | 38 | 63 | <0.001 |
| Aminoglycoside | Gentamicin | 0 | 52 | 0 | 12 | 19 | 81 | 0.002 |
| Aminoglycoside | Neomycin | 0 | 0 | 63 | 1 | 2 | 98 | 1.0 |
| Aminoglycoside | Spectinomycin | 0 | 64 | 0 | 0 | 0 | 100 | 0.37 |
| Sulfonamide | Sulfadimethoxine | 1 | 1 | 60 | 2 | 5 | 95 | 0.63 |
| Trimeth/Sulf | TMS | 33 | 21 | 7 | 3 | 56 | 44 | <0.001 |
| Pleuromutilin | Tiamulin | 0 | 40 | 0 | 24 | 37 | 63 | <0.001 |
| MLS | Clindamycin | 7 | 6 | 31 | 20 | 42 | 58 | 0.02 |
| MLS | Tilmicosin | 13 | 21 | 25 | 5 | 28 | 72 | 0.06 |
| MLS | Tulathromycin | 33 | 26 | 7 | 3 | 52 | 48 | <0.001 |
| MLS | Tylosin tartrate | 5 | 4 | 33 | 22 | 42 | 58 | <0.001 |
Pheno, phenotype; S, susceptible; R, resistant; Geno, genotype; Trimeth/Sulf, trimethoprim/sulfonamide; TMS, trimethoprim-sulfamethoxazole; MLS, macrolide-lincosamide-streptogramin.
Figure 3Prevalence of phenotypic resistance to all drugs tested among isolates of Histophilus somni (N = 13), Mannheimia haemolytica (N = 26), and Pasteurella multocida (N = 25).
Figure 4Heatmap showing concordance (blue) and discordance (red) between erm42 and ermF presence (black) or absence (gray) and phenotypic resistance to the four macrolide drugs included in the susceptibility testing panel (columns), by isolate (rows) within organism. CLIN, clindamycin; TIL, tilmicosin; TUL, tulathromycin; TYL, tylosin tartrate.